A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

Drug Category : Array
Conference Category : Array
Lead Author : Sawas, O'Connor et al.
Published Date : 16/12/2016
Download Link : http://onlinelibrary.wiley.com/doi/10.1111/bjh.14534/full
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top